scholarly journals The Heterogeneity of Clinical Practice Patterns among an International Cohort of Pulmonary Arterial Hypertension Experts

2014 ◽  
Vol 4 (3) ◽  
pp. 441-451 ◽  
Author(s):  
John J. Ryan ◽  
Ghazwan Butrous ◽  
Bradley A. Maron
2016 ◽  
Vol 6 (4) ◽  
pp. 622-622

In “An international physician survey of pulmonary arterial hypertension management,” by Preston et al. ( Pulmonary Circulation 6:338–346), several corrections by the author were not incorporated into the final print version. The following sentence was added to the end of the second paragraph: “Furthermore, a recent survey of international PAH experts has also suggested that real-world practice patterns differ from consensus recommendations and between locations.12” In the “Discussion” section, these sentences were added after the first sentence: “Another international study of PAH experts was recently published. Like our study, the survey carried out by Ryan et al.12 identified differences between consensus recommendations and clinical practices.” A new entry (12) was added to the References: Ryan JJ, Butrous G, Maron BA. The heterogeneity of clinical practice patterns among an international cohort of pulmonary arterial hypertension experts. Pulm Circ 2014;4(3):441–451. The final version of the article can be found in the online edition. The publisher regrets these errors.


2004 ◽  
Vol 3 (4) ◽  
pp. 4-23

[Editor's note: Editor-in-Chief Victor Tapson, MD, interviewed a select panel of experts in pulmonary hypertension to obtain their review and comments on the new evidence-based clinical practice guidelines of the American College of Chest Physicians. Please see the Editor's Memo for more information.]


2017 ◽  
Vol 89 (8) ◽  
pp. 95-103
Author(s):  
Z S Valieva ◽  
T V Martynyuk ◽  
I E Chazova

The results of evaluating the efficacy and safety of bosentan in patients with pulmonary arterial hypertension (PAH), as shown by the data of foreign randomized controlled trials and the authors’ own experience, convincingly demonstrate that the introduction of the drug into clinical practice has led to a significant improvement of the possibilities of drug therapy in patients with this serious illness. Bosentan substantially improves physical activity in patients, reduces the severity of clinical symptoms, slows down the rates of disease progression, and prolongs survival in patients with different forms of PAH.


CHEST Journal ◽  
2021 ◽  
Vol 160 (4) ◽  
pp. A2301-A2303
Author(s):  
Ronald Oudiz ◽  
Murali Chakinala ◽  
Robert Frantz ◽  
Adaani Frost ◽  
Lisa Lancaster ◽  
...  

2017 ◽  
Vol 26 (146) ◽  
pp. 170095 ◽  
Author(s):  
Sean Gaine ◽  
Vallerie McLaughlin

Recent advances in the treatment of pulmonary arterial hypertension (PAH) have led to improved patient outcomes. Multiple PAH therapies are now available and optimising the use of these drugs in clinical practice is vital. In this review, we discuss the management of PAH patients in the context of current treatment guidelines and supporting clinical evidence. In clinical practice, considerable emphasis is placed on the importance of making treatment decisions guided by each patient's risk status, which should be assessed using multiple prognostic parameters. As PAH is a progressive disease, regular assessments are essential to ensure that any change in risk is detected in a timely manner and treatment is adjusted accordingly. With the availability of therapies that target three different pathogenic pathways, combination therapy is now the standard of care. For most patients, this involves dual combination therapy with agents targeting the endothelin and nitric oxide pathways. Therapies targeting the prostacyclin pathway should be added for patients receiving dual combination therapy who do not achieve a low-risk status. There is also a need for a holistic approach to treatment beyond pharmacological therapies. Implementation of all these approaches will ensure that PAH patients receive maximal benefit from currently available therapies.


CHEST Journal ◽  
2020 ◽  
Vol 158 (4) ◽  
pp. A2183-A2184
Author(s):  
Karim El-Kersh ◽  
Christopher King ◽  
Eric Shen ◽  
Peter Classi ◽  
Vijay Balasubramanian

Sign in / Sign up

Export Citation Format

Share Document